The role of the tissue factor-thrombin pathway in cardiac ischemia-reperfusion injury.
This article focuses on the role of the tissue factor (TF)-thrombin pathway in cardiac ischemia-reperfusion (I/R) injury. We and others have used rabbit models of cardiac I/R injury to show that anti-TF therapy prevents the transient decrease in regional myocardial blood flow, reduces platelet and fibrin(ogen) accumulation, and reduces infarct size. At present, the mechanism by which TF-initiated coagulation contributes to myocardial injury is not established. Inhibition of TF may decrease intravascular fibrin deposition and thrombosis. However, immunohistochemical studies demonstrated that fibrin deposition was predominantly within the myocardium and depletion of fibrinogen did not reduce infarct size. In contrast, inhibition of thrombin reduced infarct size to a similar extent as anti-TF therapy. We propose that the TF-thrombin pathway may contribute to myocardial injury by an additional mechanism that is not dependent on fibrin deposition but involves activation of protease activated receptor 1 (PAR-1) on vascular endothelial cells and cardiac myocytes. Anti-TF therapy would inhibit both thrombin-dependent fibrin deposition and thrombin-dependent PAR-1 signaling.
Mackman
Nigel
N
Departments of Immunology and Cell Biology, The Scripps Research Institute, La Jolla 92037, CA, USA. n.mackman@scripps.edu
D000818:Animals; D001777:Blood Coagulation / Q000502:physiology; D015944:Factor VIIIa / Q000037:antagonists & inhibitors; D005340:Fibrinogen / Q000502:physiology; D006801:Humans; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy / Q000503:physiopathology*; D009206:Myocardium / Q000378:metabolism; D011817:Rabbits; D044463:Receptor, PAR-1 / Q000502:physiology; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000502:physiology*; D013925:Thromboplastin / Q000037:antagonists & inhibitors / Q000502:physiology*
D044463:Receptor, PAR-1; D015944:Factor VIIIa; D005340:Fibrinogen; D013925:Thromboplastin; D013917:Thrombin